Current Prospects of Rome Criteria for the Diagnosis of Irritable Bowel Syndrome

Rasha Zaid  Shammout; Mousa Numan  Ahmad

doi:10.35516/jjas.v18i1.105

Authors

Rasha Zaid Shammout University of Jordan, Amman 11942, Jordan
Mousa Numan Ahmad University of Jordan, Amman 11942, Jordan https://orcid.org/0000-0003-2863-3363

DOI:

https://doi.org/10.35516/jjas.v18i1.105

Keywords:

Irritable bowel syndrome, Rome I, II, III, IV criteria.

Abstract

Irritable bowel syndrome (IBS) is a worldwide health problem. It is often diagnosed by periodically- updated Rome symptom-based criteria, but the effects of recent updates on IBS diagnosis are not well clarified. This article overviews Rome III and IV IBS criteria, highlighting changes and updates that may impact IBS diagnosis. PubMed, Medline, Science Direct, Clinical trials.gov, and WHO databases were searched through to July 2021. Rome IV criteria are more restrictive, specific, and precise in patients′ diagnosis, selection, prognosis, and follow-up than Rome III criteria, in turn, IBS prevalence and number of patients with IBS-unspecified and IBS-mixed subtypes decrease, but overall symptom severity and patients′ homogeneity increase. In essence, the slight difference between Rome III and IV criteria reflects a considerable influence on IBS diagnosis, subtyping, and prevalence. Rome IV IBS patients form a homogeneous subset of Rome III IBS patients with more severe symptoms. Thus, in-depth research is warranted.

Downloads

Download data is not yet available.

Author Biographies

Rasha Zaid Shammout, University of Jordan, Amman 11942, Jordan

Department of Nutrition and Food Technology, Human Nutrition and Dietetics, University of Jordan, Amman 11942, Jordan

Mousa Numan Ahmad, University of Jordan, Amman 11942, Jordan

Department of Nutrition and Food Technology, Human Nutrition and Dietetics, University of Jordan, Amman 11942, Jordan

References

Algera, J., Colomier, E., Simrén, M. (2019). The dietary management of patients with irritable bowel syndrome: a narrative review of the existing and emerging evidence. Nutrients, 11(9):2162. doi:10.3390/nu11092162

Aziz, I., Tornblom, H., Palsson, O.S., Whitehead, W.E., Simrén. M. (2018). How the change in IBS criteria from Rome III to Rome IV impacts clinical characteristics and key pathophysiological factors. American Journal of Gastroenterology. 113(7):1017-1025. DOI: 10.1038/s41395-018-0074-z.

Barandouzi, Z.A., Lee, J., Maas, K., Starkweather, A.R., Cong, X.S. (2021). Altered gut microbiota in irritable bowel syndrome and its association with food components. Journal of Personal Medicine. 11(1): 35. https://doi.org/10.3390/jpm11010035.

Begtrup, L.M., Engsbro, A.L., Kjeldsen, J., Larsen, P.V., de Muckadell, O.S., Bytzter, P., et al. (2013). A positive diagnostic strategy is non-inferior to the strategy of exclusion for patients with irritable bowel syndrome. Clinical Gastroenterology and Hepatology. 11(6):956962. doi:10.1016/ j.cgh.2012.12.038.

Black, C.J., Craig, O., Gracie, D.J., Ford, A.C. (2021). Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gut. 70(6): 1110–1116. https://doi.org/10.1136/gutjnl-2020-322519.

Black, C.J., Yiannakou, Y., Houghton, L.A., Ford, A.C. (2020). Epidemiological, clinical, and psychological characteristics of individuals with self-reported irritable bowel syndrome based on the Rome IV vs Rome III criteria. Clinical Gastroenterology and Hepatology. 18(2):392-398. e2. DOI: 10.1016/ j.cgh.2019.05.037.

Camilleri, M. (2021). Diagnosis and treatment of irritable bowel syndrome: a review. Journal of American Medical Association. 325(9): 865–877. https://doi.org/10.1001/jama.2020.22532.

Drossman, D.A. (2016). Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology. 150:1262-1279. DOI: 10.1053/j.gastro.2016.02.032.

Drossman, D.A., Corazziari, E., Delvaux, M., Spiller, R.C., Talley, N.J., Thompson, W.G., et al. (2006). Rome III: The Functional Gastrointestinal Disorders. VA: Degnon Associates, McLean.

Drossman, D.A., Funch-Jensen, P., Janssens, J., Talley, N.J., Thompson, W.G., Whitehead, W.E. (1990). Identification of subgroups of functional bowel disorders. Gastroenterology International. 3:159-172.

Drossman, D.A., Richter, J.E., Talley, N.J., Thompson, G.W., Corazziari, E., Whitehead, W.E. (1994). The Functional Gastrointestinal Disorders. Diagnosis, Pathophysiology and Treatment-A Multinational Consensus. Boston, Little Brown, and Co.

Ford, A.C., Moayyedi, P., Chey, W.D., Harris, L.A., Lacy, B.E., Siato, Y.A., et al. (2018). American College of Gastroenterology monograph on the management of irritable bowel syndrome. American Journal of Gastroenterology. 113(2):1-18. https://doi.org/10.1038/s41395-018-0084-x.

Herndon, C.C., Wang, Y.P., Lu, C.L. (2020). Targeting the gut microbiota for the treatment of irritable bowel syndrome. Journal of Medical Science. 36(3):160-170. https://doi.org/10.1002/kjm2.12154.

Irvine, A.J., Chey, W.D., Ford, A.C. (2017). Screening for celiac disease in irritable bowel syndrome: an updated systematic review and meta-analysis. American Journal of Gastroenterology. 112(1):65-76. DOI: 10. 1038/ajg.2016.466.

Klein, K.B. (1988). Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology. 95(1):232-241. DOI: 10.1016/0016-5085(88)90319-8.

Kruis, W., Thieme, C., Weinzierl, M., Schüssler, P., Holl, J., Paulus, W. (1984). A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease. Gastroenterology. 87(1):1-7. PMID: 6724251.

Lacy, E., Mearin, F., Chang, L., Lembo, A.J., Simrén, M., Spiller, R., et al. (2016). Bowel disorders. Gastroenterology. 150(6):1393-1407. https://doi.org/10.1053/j.gastro.2015.02.031.

Lacy, E., Patel, K. (2017). Rome criteria and a diagnostic approach to irritable bowel syndrome. Journal of Clinical Medicine. 6(11):99. DOI: 10.3390/jcm6110099.

Lewis, S.J., Heaton, K.W. (1997). Stool form scale as a useful guide to intestinal transit time. Scandinavian Journal of Gastroenterology. 32(9):920-924. DOI: 10.3109/00365529709011203.

Lin, L., Chang, L. (2020). Benefits and pitfalls of change from Rome III to Rome IV criteria for irritable bowel syndrome and fecal incontinence, Clinical Gastroenterology and Hepatology. 18(2):297-299. DOI: 10. 1016/j.cgh.2019.10.004.

Longstreth, G.F., Thompson, W.G., Chey, W.D., Houghton, L.A., Mearin, F., Spiller, R.C. (2006). Functional bowel disorders. Gastroenterology. 130(5):1480–1491. doi:10.1053/j.gastro. 2005.11.061.

Manning, A.P., Thompson, W.G., Heaton, K.W., Morris, A.F. (1978). Towards positive diagnosis of the irritable bowel. British Medical Journal. 2(6138):653–954. https://doi.org/10.1136/bmj. 2.6138.653.

Oka, P., Heather, P., Barberio, B., Black, C.J., Savarino, E.V., Ford, A.C. (2020). The global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterology and Hepatology. 5(10):908-917. doi:10.1016/ S2468-1253(20) 30217-X.

Palsson, O.S., Whitehead, W., Tornblom, H., Sperber, A.D., Simren, M. (2020). Prevalence of Rome IV functional bowel disorders among adults in the United States, Canada, and the United Kingdom. Gastroenterology. 158(5):1262-1273. DOI: 10.1053/j.gastro.2019.12.021.

Palsson, O.S., Whitehead, W.E., van Tilburg, M.A.L., Chang, L., Chey, W., Crowell, M.D., et al. (2016). Development and validation of the Rome IV diagnostic questionnaire for adults. Gastroenterology. 150(6):1481–1491. https://doi.org/10.1053/j.gastro.2016.02.014.

Rome foundation official website, www.theromefoundation.org, accessed July 2021.

Schmulson, M.J., Drossman, D.A. (2017). What is new in Rome IV. Journal of Neurogastroenterology and Motility. 23(2):151-163. doi: 10.5056/jnm16214.

Slattery, S.A., Niaz, O., Aziz, Q., Ford, A.C. (2015). Farmer, A.D. Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhea. Alimentary Pharmacology and Therapeutics. 42(1): 3–11. https://doi.org.10.1111/apt.13227.

Sperber, A.D., Bangdiwala, S.I., Drossman, D.A., Ghoshal, U.C., Simren, M., Tack, J., et al. (2021). Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study. Gastroenterology. 160(1):99-114. e3. DOI: 10.1053/j.gastro. 2020.04.014.

Sperber, A.D., Bangdiwala, S.I., Drossman, D.A., Ghoshal, U.C., Simren, M., Tack, J., et al. (2021). Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study. Gastroenterology. 160(1): 99–114. e3. https://doi.org/10.1053/ j.gastro.2020.04.014.

Thompson, W.G. (2006). The road to Rome. Gastroenterology. 130(5):1552–1556. doi:10.1053/j. gastro.2006.03.011.

Thompson, W.G., Creed, F.H., Drossman, D.A., Heaton, K.W., Mazzacca, G. (1992). Functional bowel disorders and functional abdominal pain. International Journal of Gastroenterology. 5:75-91.

Thompson, W.G., Dotevall, G., Drossman, D.A., Heaton, K.W., Kruis, W. (1989). Irritable bowel syndrome: guidelines for the diagnosis, International Journal of Gastroenterology. 2:92-95.

Thompson, W.G., Longstreth, G.F., Drossman, D.A., Heaton, K.W., Irvine, E.J., Muller-Lissner, S.A., et al. (1999). Functional bowel disease and functional abdominal pain, Gut. 45(S2): 1143-1147. https://doi.org/10.1136/gut.45.2008.ii43.

Vork, L., Weerts, Z.Z.R.M., Mujagic, Z., Kruimel. J.W., Hesselink, M.M., Muris, J.W.M., et al. (2018). Rome III vs Rome IV criteria for irritable bowel syndrome: a comparison of clinical characteristics in a large cohort study. Journal of Neurogastroenterology and Motility. 30:2. DOI: 10.1111/nmo. 13189.

Wang, B., Zhao, W., Zhao, C. (2019). What impact do Rome IV criteria have on patients with IBS in China? Scandinavian Journal of Gastroenterology. 54(12):1433-1440. doi:10.1080/00365521.2019. 1698650.

Whitehead, W.E., Drossman, D.A. (2010). Validation of symptom-based diagnostic criteria for irritable bowel syndrome: a critical review. American Journal of Gastroenterology. 105(4):814-820. DOI: 10.1038/ajg. 2010.56.

Whitehead, W.E., Palsson, O.S., Feld, A.D., Levy, R.L., Kroff, M.V., Turner, M.J. (2006). Utility of red flag symptom exclusions in the diagnosis of irritable bowel syndrome. Alimentary Pharmacology and Therapeutics. 24(1):137–146. DOI: 10.1111/j.1365-2036.2006.02956. x.

Whitehead, W.E., Palsson, O.S., Simren, M. (2017). Irritable bowel syndrome: what do the new Rome IV diagnostic guidelines mean for patient management? Experimental Review in Gastroenterology and Hepatology. 11(4),281-283. DOI: 10.1080/17474124.2017.1292130.